Help us: Donate
Follow us on:

The Maximon Longevity Prize for Translational Research

This prize focuses on early-stage research that shows potential.

Maximon logoMaximon logo

The investment firm Maximon is awarding a prize of 50,000 Swiss francs to an organization that Maximon believes has engaged in research that is likely to improve healthspan and lifespan in humans. The full press release is provided here.

Maximon, Europe’s first longevity company builder, is launching the Maximon Longevity Prize for Translational Research, awarding breakthrough research in the field of longevity that has the potential to substantially increase the health-span or lifespan of humans.

Maximon pledges 50,000 CHF for the winner of the prize and commits to attracting more donors and sponsors to further support the cause. Two of Maximon’s ventures also pledge exclusive rewards for the prize recipient: Biolytica will provide a personalised longevity concierge program at the value of 20,000 CHF, and Avea will supply the winner with a one-year subscription for its science-based longevity supplements at the value of 5,000 CHF.

The prize is open to applications from all academic/non-profit researchers, inventors, scientists, students, or startup founders who either published their breakthrough research, hold the patent, or are in very advanced stages of research. The application window will be open for six months, starting on the 1st of March until the 31st of July 2022. You can apply here:

“We are on a mission to extend the human health-span helping people to stay fit, healthy, and happy until old age. We believe that supporting bold breakthrough ideas and the scientists behind them is much neede to speed-up the translation of science to products and services available to everyone”, says Dr. Tobias Reichmuth, Founding Partner of Maximon. “With this prize, we are hoping to bridge the gap between science and clinic. Give exceptional researchers the resources they need to expand their work and accelerate their research to find interventions for a longevity society”, adds Dr. Ashish Rajput, Chief Scientific Officer at Maximon and member of the Jury Committee of the prize. Other members of the Jury include Prof. Brian Kennedy, Distinguished Professor, Department of Biochemistry and Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Prof. Dr. Collin Ewald, Assistant Professor at ETH Zurich.

The evaluation phase will take place in August 2022 and will culminate with a presentation of the top 3 finalists during the Longevity Investors Conference (LIC), taking place on September 28-30 at Le Grand Bellevue Hotel in Gstaad, Switzerland. The conference is the world’s leading and most private investors-focused conference in the field of longevity. The LIC brings together the most renowned longevity scientists, private and institutional investors, and family offices. The winner will be announced during a prize ceremony at the LIC Gala Dinner taking place on September 29 in Le Grand Bellevue Hotel, Gstaad.

For more information, please visit

Maximon AG

Bahnhofplatz CH-6300 Zug Switzerland

[email protected]

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Longevity Investors Lunch at Davos

A Longevity Investors Lunch hosted by Maximon, Longevity Investors Conference, and Biolytica has been hosted at a satellite event of...

Open Longevity Foundation Announces Open Genes Database

Open Longevity Foundation has announced Open Genes, a database of longevity-associated genes and a tool for future anti-aging therapy development....

Gero Enters Research Collaboration with Pfizer

Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform...

Immunis Begins Clinical Trial of Stem Cell Secretome

Intending to treat sarcopenia, the private biotechnology company Immunis has begun a human clinical trial of a stem cell secretome...

CategoryPress Releases
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.